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Abstract 
In estrogen deficient postmenopausal women, osteoporosis shares a common link with 
cardiovascular disease risk, including endothelial dysfunction. The current study sought to examine 
associations between bone mineral density (BMD) and endothelial function in estrogen deficient 
premenopausal women with exercise-associated menstrual disturbances. Recreationally trained 
women (24.3±0.8 years; overall mean±SEM) who were estrogen deficient (amenorrheic or 
eumenorrheic anovulatory cycles; E2Def; n=13) or estrogen replete (eumenorrheic ovulatory cycles; 
E2Rep; n=14) were studied.   Total body and lumbar BMD (L1-L4) were determined using dual energy 
X-ray absorptiometry.  Serum markers of oxidative stress (oxidised low-density lipoprotein; OxLDL), 
energy deficiency (triiodothyronine), and bone turnover (osteocalcin, c-telopeptide X, P1NP) were 
assessed. Estrogen exposure was determined by assessing daily urinary estrone-3-glucuronide (E1G) 
across a monitoring period. Calf blood flow (CBF), an index of endothelial function, was measured 
using strain-gauge plethysmography. CBF, total body and L1-L4 BMD, triiodothyronine and E1G were 
lower (p<0.05), and c-telopeptide crosslinks higher (p<0.05) in E2Def.  Osteocalcin and OxLDL did not 
differ (p>0.05) between groups.  L1-L4 BMD, osteocalcin and E1G were the strongest predictors of 
CBF (R2=0.615, p<0.001). CBF was the strongest predictor of L1-L4 BMD (R2=0.478, p<0.001).  L1-L4 
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(r=0.558, p=0.008) and CBF (r=0.534, p=0.004) were independently correlated with E1G. In young 
recreationally trained premenopausal women with anovulatory menstrual disturbances, low CBF 
predicts decreased lumbar BMD, suggesting impaired peripheral endothelial function may predict 
early unfavorable changes in bone metabolism.  This finding may be of relevance in the early 
detection of cardiovascular and bone health decrements in otherwise healthy estrogen 
deficient premenopausal women.  
 
Introduction 
Cardiovascular disease (CVD) and osteoporosis are recognized major public health problems 
1,2, with growing evidence indicating that these diseases are linked.  Low bone mineral 
density (BMD) is associated with endothelial dysfunction 3, coronary artery disease 1,2, 
peripheral vascular disease 4, stroke 5 and cardiovascular mortality 2,6.  Sex differences in 
this relationship are also reported, with some studies demonstrating a stronger link between 
bone health and CVD in women compared with age-matched men 5,7, suggesting a possible 
role for estrogen 5,7.  Estrogen is known to upregulate the production and bioavailability of 
endothelium-derived nitric oxide (NO), a key molecule that modulates both vascular tone and 
bone resorption 8,9.  Conversely, estrogen deficiency is associated with decreased circulating 
levels of NO 9 and increased risk of osteoporosis and cardiovascular disease 8,9.  
Estrogen deficiency is not exclusive to the postmenopausal period.  During the 
premenopausal years, exercise-associated menstrual disturbances such as hypothalamic 
anovulation, either with eumenorrhea or amenorrhea, are characterized by marked 
hypoestrogenemia 10,11. The prevalence of eumenorrheic anovulation (16-25%) and 
amenorrhea (1-60%) is markedly higher in recreationally and competitively active women 
compared with sedentary women (5-8% and 2-5%, respectively) 12-15.  Chronic energy 
deficiency due to high energy expenditure that is often combined with restrictive eating 
patterns that can occur with or without out obvious caloric deficits has been identified as the 
primary cause of these menstrual disturbances 16.    
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The current study sought to examine the relationship between BMD and endothelial 
function, a surrogate marker of CVD risk, in estrogen deficient recreationally active women 
with exercise-associated menstrual disturbances.  We also investigated whether estrogen 
exposure, as determined by daily urinary analysis of estrogenic metabolites across a 
monitoring period, and serum measures of triiodothyronine, a marker of energy status 17, 
commonly linked impaired bone and vascular health.  Oxidative stress, a known contributing 
factor to both osteoporosis and CVD 18,19, was also assessed for possible shared links due to the 
known anti-oxidant effects of estrogen 20. In keeping with previous findings in amenorrheic 
athletes 10,21-23, we anticipated that estrogen deficient women would demonstrate impaired 
endothelial function and lower BMD compared with their estrogen replete counterpart. We 
hypothesized that impaired endothelial function would be associated with lower BMD, and 
that these perturbations would be commonly linked with estrogen exposure, and markers of 
energy deficiency and oxidative stress.   
 
Materials and Methods 
Participants:  Participants were recruited by posters. Physical activity status was required to 
have been consistent for the previous 6 months. Eligibility criteria for the study included: 1) 
age 18 to 35 years; 2) self-reported good health; 3) no known chronic illness, including 
hyperprolactinemia, metabolic syndrome, polycystic ovarian syndrome and thyroid disease; 
4) stable menstrual status over preceding 3 months (menstruating or absence of menses); 5) 
non-smoking; 6) not currently dieting and weight stable for the preceding 3 months, as 
determined by self-report; 7) absence of hormonal therapy for at least 12 months; 8) no 
history or current clinical diagnosis of eating disorders and 9) no other contraindications that 
would preclude participation in the study.  The study was approved by the institutional 
committee on human research by the Ethics Review Board, and confirmed to the standards 
set by the latest revision of the Declaration of Helsinki.  All volunteers signed an approved 
informed consent document. 
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Experimental Design:  The current investigation forms part of a larger prospective 
observational study examining relationships between physical activity, reproductive function, 
and bone and cardiovascular health.  Fifty-two women completed 1-3 studies from the larger 
study over a 2-3 year window, with each woman being assessed across 2-3 consecutive 
menstrual cycles. From this cohort, we have previously published data on calf blood flow 10,24 
and bone health 21.  The current study presents novel analysis of the association between 
cardiovascular and bone health in two unique groups comprised of age-, body-composition-, 
and fitness-matched women who were either estrogen deficient (functional hypothalamic 
amenorrhea or eumenorrheic anovulatory cycles), or estrogen replete (eumenorrheic 
ovulatory cycles).   
 
Experimental Protocol: All testing was completed in an ambient room (22-24°C) between the 
hours of 08:00 and 11:00.  Except for maximal oxygen capacity testing, participants were 8 
hours (overnight) fasted and had abstained from physical activity and caffeine for 24 hours 
and alcohol 12 hours prior to each study visit.  All measures, except urine measures which 
were assessed daily, were recorded during the first 6-days of each menstrual cycle and 
during the first 6-days of each 30-day monitoring period for amenorrheic women.  Subjects 
were monitored for 2 to 3 consecutive menstrual cycles or monitoring periods.  Measures 
collected during 2 to 3 menstrual cycles were averaged for statistical analyses. 
 
Exercise Status: Participants were required to be participating in purposeful exercise eliciting 
a heart rate (HR) greater than 55% of maximal HR (220 minus age) for more than 2 hours 
per week, and demonstrate a VO2 peak >40 ml/kg/min  
10.  Exercise logs documented 
exercise type, duration, and HR.  
 
Menstrual Status: Menstrual status was determined from daily first morning void urine 
samples. Urine samples were assayed for luteinizing hormone (LH), pregnanediol 3-
glucuronide (PdG), and estrone 3-glucuronide (E1G) to assess ovulatory status and 
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estrogen exposure. We have previously described the criteria for detection of positive 
ovulation and menstrual cycle status 10. Amenorrhea was defined as cessation of menses for 
>90 days.  Anovulatory menstrual status was identified as presentation of consistent 
anovulatory menstrual cycles for the study duration.   
 
Study Groups: Two groupings of physically active women were retrospectively established: 
1) estrogen replete (E2Rep; n=14) with eumenorrheic ovulatory menstrual cycles; and 2) 
estrogen deficient (E2Def; n=13) with eumenorrheic anovulatory menstrual cycles (n=4) and 
functional hypothalamic amenorrhea (n=9).   
 
Estrogen Exposure: Using daily urinary estrogen levels, estrogen exposure (E1G) across 
each menstrual cycle or monitoring period was calculated by the trapezoidal area under the 
curve (AUC) method 10.   
 
Anthropometric Measures: Average total body mass was determined from weekly measures 
on a physician’s balance scale (Detecto, Webb City, MO). Height was measured at the 
beginning of the study period. Body mass index (BMI; kg/m2) was calculated (mean body 
weight (kg) divided by height2).  
 
Body Composition and Bone Mineral Density: DXA was utilized to determine body 
composition and BMD (Prodigy, General Electric Lunar Corporation, Madison, WI, enCORE 
2002 software, version 6.50.069).  Total body and lumbar spine (L1-L4) BMD (absolute, 
g/cm2 and Z-scores) were determined. A 28 subject precision study demonstrated 0.6 and 
0.7 % precision for the total body and lumbar spine, respectively. The DXA scanner has a 
precision of < 1% coefficient of variation for body composition measurements.  
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Peak Aerobic Capacity: VO2 peak was measured once by a progressive treadmill test to 
volitional exhaustion. Expired gases were collected continuously to measure inspired air 
volumes and to analyze breath-by-breath samples (Moxus Modular VO2 System, Applied 
Electrochemistry Inc., Pittsburgh, PA). 
 
Calf Blood Flow, Heart Rate and Blood Pressure:  Calf blood flow (CBF), an index of 
endothelial function, was assessed using venous occlusion strain-gauge plethysmography 
as previously described by our group 10,24.  In brief, with the subject in a supine position, a 
cuff was placed at the ankle (200mm Hg) and above the knee (55mmHg).  An indium-gallium 
strain gauge (Vasculab SPG16 Medasonics, Newark, CA) was placed around the widest 
girth of the calf.  Baseline resting and peak-ischemic measures were acquired. Ischemic 
plantar flexion exercise to fatigue was employed to elicit a maximal peak-response.  Blood 
flow (mL/100mL/min), vascular conductance (blood flow/ mean arterial pressure (MAP); 
mL/100mL/min/mmHg), and vascular resistance (MAP/blood flow; U) were calculated. 
Measurement of HR and mean arterial pressure blood pressure (BP) were recorded 
continuously throughout each testing session on a beat-to-beat basis using the 
photoplethysmographic method (Finapres, Ohmeda, Madison, WI). 
 
Serum Measures: Eight-hour fasted blood samples were analyzed for osteocalcin, c-
telopeptide (CTX), procollagen type 1 N propeptide (P1NP), total triiodothyronine (TT3), and 
oxidized low-density lipoproteins (OxLDL). Serum samples were stored at -80°C until 
analyses were run.  Osteocalcin was analyzed using an enzyme immunoassay technique 
(Quantikine Assay Kit, DRP300, R&D Systems Inc., Minneapolis, MN).  Sensitivity was 
0.246 ng/mL.  The intraassay and interassay coefficients of variation (CV) were 4.7%, and 
6.9% respectively.  CTX was analyzed using a direct sandwich enzyme-linked 
immunosorbent assay (ELISA, Linco Research, Inc., St. Charles, MO).  Analytical sensitivity 
was 0.5 ng/mL. The intra- and interassay CV were 4.6% and 6.2% respectively.  P1NP was 
determined using a chemiluminescence-based immunoassay analyzer (Immulite, Diagnostic 
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Products Corp.). The analytical sensitivity of the assay was 2 µIU/ml (14.4 pmol/L). The intra 
and interassay CV were 6.4% and 8.0%, respectively.  TT3 , an indirect marker of energy status 
17, was analyzed using a chemiluminescence-based immunoassay analyzer (Immulite, Diagnostics 
Products Corporation, Los Angeles, CA). Analytical sensitivity for insulin was 13.89 pmol L-1, and for 
the TT3 assay was 0.54 nmol L
-1.  OxLDL, an indirect measure of systemic oxidative stress, specifically 
lipid oxidative damage, was determined with an ELISA plate assay (Alpco Diagnostics, Windham, NH, 
and R&D Systems, Minneapolis, MN).  Analytical sensitivity was ≥0.03 U/I.  Intra- and interassay 
coefficients of variation were both 5.75 U/I. 
 
Urinary Measures: Measures of daily urinary metabolites were determined using microtiter 
plate competitive enzyme immunoassays to detect pregnanediol 3-glucuronide (PdG), and 
estrone 3-glucuronide (E1G).  Detailed methods for these immunoassays have been 
described previously 10,24.  The inter-assay coefficients of variation for high and low internal 
controls were 14.7% and 13.1% for E1G and 15.68% and 17.7% for PdG.  To account for 
hydration status, urine samples were corrected for specific gravity using a hand 
refractometer (NSG Precision Cells, Inc., Farmingdale, NY).  
Urinary LH, assessed in ovulatory women only, was determined by double antibody 
radioimmunoassay (Diagnostic Products Corp., Los Angeles, CA). The sensitivity of the LH 
assay was 0.6 mIU L-1. The intra-assay and inter-assay coefficients of variation were 1.6% 
and 7.1%, respectively.  
 
Statistics:  Data screening for outliers and heteroscedasticity was conducted prior to 
statistical analysis. No outliers were detected and all data were normally distributed.  
Comparison of data between the groups was analyzed using independent samples t-test.  
Using pooled data, Pearson’s bivariate correlational analyses were used to determine 
significant linear independent associations of interest.  Running separate analyses, mixed 
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model linear regression using stepwise methods (P=0.15 for entry, and P=0.20 to leave the 
model) were used to explore predictors of calf blood flow and bone health.  This method of 
inclusion was selected to account for potential confounding effects of various variables (e.g., 
inflation of the standard error due to collinearity), and to rule out the masking of associations 
of independent variables with the dependent variable because of confounders.  Data were 
analyzed using SPSS version 23.0 (SPSS Inc., Chicago, IL).  A significance level of p<0.05 
was used to detect group differences. All data are presented as the mean ± SEM. 
 
Results 
Subject characteristics: Group characteristics are shown in Table 1.  E2Def and E2Rep did 
not differ (p>0.05) in age, height, weight, body composition, or cardiorespiratory fitness.  In 
contrast, MAP, HR and TT3 were lower (p<0.05) in E2Def. Estrogen deficient amenorrheic 
women and estrogen deficient women with eumenorrheic anovulatory menstrual cycles did 
not differ (p>0.05) in age, body composition, cardiorespiratory fitness level, BMD measures, 
serum bone turnover markers, resting calf blood flow, triiodothyronine, or estrogen exposure 
levels (data not shown).  
 
Menstrual Cycle Characteristics and Urinary Ovarian Steroids: Average cycle length did not 
differ (p>0.05) between eumenorrheic ovulatory women (29±1 day) and eumenorrheic 
anovulatory women (28±1 day). Age of menarche was higher (p<0.05) in E2Def (13.2±0.4 
years) versus E2Rep (12.1±0.3 years).  Average duration of amenorrhea for the 
amenorrheic women was 176±45 days at study entry.  Urinary E1G AUC and E1G mean, 
and PdG AUC and PdG mean were significantly lower (p<0.05) in E2Def (Table 1).   
  
Bone Mineral Density and Calf Blood Flow: Total body BMD and L1-L4 BMD were lower 
(p<0.05) in E2Def (Table 2). Serum P1NP and osteocalcin did not differ (p>0.05) between 
groups.  In contrast, CTX was higher (p<0.05) in E2Def.  
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Resting CBF was lower (p<0.05) in E2Def, but peak CBF did not differ (p>0.05) 
between the groups (Table 2). In keeping with this, resting calf vascular conductance was 
lower (p<0.05) and vascular resistance higher (p<0.05) in E2Def, but peak vascular 
conductance and resistance did not differ (p>0.05) between groups.  
 
Independent Correlations of Bone and Cardiovascular Health: Using pooled data for 
bivariate correlations (see Figure 1), L1-L4 BMD was independently associated with CBF 
(r=0.701, p<0.001), CTX (r= -0.502, p=0.012), and E1G AUC (r=0.512, p=0.008).  CBF was 
independently associated with L1-L4 BMD (r=0.701, p<0.001), and E1G AUC (r=0.541, 
p=0.004). Triiodothyronine and OxLDL did not correlate (p>0.05) with either BMD or CBF. 
 
Bone Indices as a Predictor of Endothelial Function:  Using pooled data for stepwise linear 
regression, we explored whether estrogen and varied indices of bone health were able to 
predict endothelial function, as determined by resting CBF.  Variables in the regression 
model included: L1-L4 BMD, E1G AUC, and osteocalcin.  Osteocalcin levels are positively 
associated with cardiovascular disease risk in older estrogen deficient women 25. Using this 
model, CBF was predicted by L1-L4 BMD, osteocalcin and E1G AUC (see Table 3), 
explaining ~63% of the variance (adjusted R2=0.633, F=14.827, p<0.001).   
 
Cardiovascular Indices as a Predictor of Bone health: Using pooled data for stepwise 
regression, we examined whether estrogen and varied indices of cardiovascular health could 
predict L1-L4 BMD.  Variables in the regression model included: resting CBF, E1G AUC and 
OxLDL.  OxLDL is reported to modulate the crosstalk between osteoblasts/osteoclasts, promoting 
increased osteoclast differentiation and bone resorption 18.  We report that the strongest 
predictor of L1-L4 BMD was CBF (Table 3), explaining ~48% of the variance (adjusted 
R2=0.478, F=22.937, p<0.001).  
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Discussion 
Consistent with previous studies in 10,21,26, we demonstrate that compared with their estrogen 
replete counterpart, estrogen deficient women with exercise associated menstrual disturbances 
demonstrate impaired endothelial function and lower total body and lumbar spine BMD. For the first 
time, we report endothelial function in the lower limb skeletal muscle vascular bed is predicted by 
L1-L4 BMD and osteocalcin. A reciprocal link was also observed, with L1-L4 BMD identified as the 
strongest predictor of endothelial function. Estrogen exposure, but not OxLDL or TT3, was positively 
associated with both L1-L4 BMD and endothelial function. 
These observations suggest that in recreationally trained premenopausal women with menstrual 
disturbances: i) impaired vascular and bone health are linked; ii) peripheral vascular function may be 
a sentinel for early changes in bone metabolism, and vice versa; and iii) estrogen deficiency, but not 
oxidative stress or energy deficiency, may be a common mechanism in this bidirectional association.  
 
Associations between vascular and bone health 
In the current study, we report lower total body and L1-L4 BMD and lower CBF, an index of 
endothelial function, in our estrogen deplete versus replete women.  These findings are consistent 
with previous studies in amenorrheic versus eumenorrheic recreational and competitive athletes 
10,21,23,26.  Our novel findings identify that these perturbations are bidirectionally associated such 
that L1-L4 BMD predicts CBF, and vice versa. It is not yet known whether such associations can 
predict future bone or cardiovascular health risk. Notwithstanding, low bone mineral content in the 
forearm at menopause is associated with an increased future risk of cardiovascular mortality 27.  
Endothelial dysfunction is also a recognised key permissive factor in the development and 
progression of atherosclerosis 28 and is reported to be evident decades prior to overt 
coronary artery disease 29.  However, the long-term clinical consequence of impaired endothelial 
function in young otherwise healthy estrogen deficient physically active women are not yet known.  
Nevertheless, independent of other risk factors, premenopausal estrogen deficiency due to 
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functional hypothalamic amenorrhea is reported to be a risk factor for angiographically documented 
coronary artery disease during the late premenopausal years 30.  Prospective studies in estrogen 
deficient physically active women to determine whether impaired endothelial function elicits 
premature development of atherosclerosis, or whether lumbar bone loss during the premenopausal 
years can predict future cardiovascular disease risk, will be of clinical interest.  
Our observations are in keeping with studies in older estrogen deficient postmenopausal 
women 3,31,32.  For example, impaired brachial artery endothelial function using ultrasonography is 
associated with lower L2-L4 BMD using DXA, with age-adjusted analysis revealing osteoporotic 
women demonstrate significantly greater impairments to endothelial function than those with 
normal BMD 3.  Decreased vascular blood flow in the lower extremities detected with Doppler 
flowmetry has also been reported to be associated with low BMD at the hip and calcaneus as 
assessed by single photon absorptiometry in postmenopausal women 31.  In contrast to the previous 
study 3, adjustment for age removed these associations. Equivocal findings for the effects of age on 
these associations likely reflect in part the shared risk of ageing on both diseases 1. 
Smoking, low physical activity, and elevated BMI are also recognized common risk factors for 
decreased BMD and increased cardiovascular disease risk 1.  In the current study, participants were 
young, non-smoking, of normal body composition and body weight, and demonstrated good 
cardiorespiratory fitness levels.  Thus, in the absence of shared risk factors, it is plausible that in our 
young otherwise healthy premenopausal women, estrogen deficiency per se may be a shared 
mechanism in the pathophysiology of these conditions.  In support of this notion, and consistent the 
known biological effects of estrogen on cardiovascular and bone health, we observed strong 
independent and positive correlations between urinary E1G and CBF and BMD.  In the vasculature, 
estrogen is a key regulator of vascular function in women.  Estrogen elicits rapid vasodilation 
through upregulation of the production of nitric oxide (NO) via the endothelium nitric oxide synthase 
(eNOS) pathway 9.  NO derived from this pathway increases blood flow, both within the arterial tree 
9 and in the bone circulation 33.  Bone is highly vascularized, and circulation is vital to bone 
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development, maintenance and repair 1,33. Thus, it is plausible that blood flow may be impaired in 
both the peripheral and bone circulation in estrogen deficient women and that, if evident, peripheral 
blood flow could be a surrogate marker of impaired bone circulation and/or bone health.  In keeping 
with this notion, ovariectomy in animals induces decreased vertebral bone health in association with 
increased vascular dysfunction in the periphery, and decreased bone vessel motility and blood flow 
34.   
 
Exercise Training and Bone and Vascular Health 
In the vasculature, dynamic exercise training elicits changes in functional (e.g., increased sensitivity 
to vasoactive substances) and structural components (e.g., increased vessel diameter) as a 
consequence of repeated hemodynamic forces on the vessel wall 35.  In bone, weight-bearing 
exercise exerts mechanical forces on the skeleton that can stimulate osteogenic and bone anabolic 
effects, having beneficial effects on bone density, size, and shape 36. These exercise-associated 
benefits are associated with decreased risk of cardiovascular disease and osteoporosis 35,36.  In 
contrast, we report that despite participation in regular load-bearing exercise training, our estrogen 
deplete women demonstrate lower lumbar and total BMD and lower CBF than their estrogen replete 
counterpart. Given that both groups report similar levels of exercise training and demonstrate 
similar cardiorespiratory fitness, these findings suggest the bone and vascular benefit of exercise 
may be obviated in the face of estrogen deficiency.  This notion is consistent with findings in exercise 
trained estrogen deficient postmenopausal women.  For example, negligible osteogenic and bone 
anabolic effects of dynamic weight-bearing exercise training 37 and lack of an attenuated age-
associated increase in endothelial function in habitually endurance trained versus untrained 
postmenopausal women has been reported 38.  While estrogen deficiency per se is implicated in 
these findings, estrogen deficiency-mediated increases in oxidative stress is also postulated to play a 
role 19,38.  Estrogen exerts potent anti-oxidant effects by scavenging free radicals and preventing lipid 
peroxidation 20.  In contrast, we report similar oxidative stress levels, as determined by lipid 
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peroxidation, despite marked differences in estrogen exposure between our estrogen deplete versus 
replete women.  We also did not observe independent associations between OxLDL and BMD or 
endothelial function.  This finding suggests that unlike older estrogen deficient women, oxidative 
stress may not be augmented, and/or antioxidant status is well preserved in otherwise healthy 
young estrogen deficient women.   
 
Limitations 
In the current study, we report associations only, not mechanisms of action, nor do we 
demonstrate causality.  As such, our findings should be interpreted appropriately. The 
primary cause of menstrual disturbances in physically active women has been identified as 
energy deficiency 16. Although we assessed circulating levels of triiodothyronine, a 
recognized marker of energy status, we were not able to directly assess the effects of 
energy deficiency per se on bone and cardiovascular health.  Endothelial dysfunction is 
recognized as a key permissive factor in the development and progression of atherosclerosis 
28.   Regional blood flow, as assessed using plethysmographic techniques, is a validated 
surrogate measure of endothelial function 39.  However, the long-term cardiovascular 
consequences of decreased calf blood flow in amenorrheic physically active young women 
has yet to be determined.  Examination of premenopausal women with similar menstrual 
disturbances due to different etiology (e.g., non-exercise associated menstrual 
disturbances), or participating in high impact versus low impact exercise training, may result 
in different associations between estrogen status, and cardiovascular and bone health.  
Bone quantity (i.e., BMD by DXA) is only one component of bone health.  Bone quality 
parameters, such as microarchitecture and strength, might also be important to assess.  We 
also note that while the E2Def group had lower total body and L1-L4 BMD compared to the 
E2Rep group (~5% and ~13% lower, respectively), Z-scores (~61% and ~143% lower, 
respectively) were still within the expected range for age. Notwithstanding, these early 
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changes may influence bone health trajectory such that they may be, or become, clinically 
relevant over time.   
 
Conclusion 
We report for the first time that in otherwise healthy young estrogen deficient physically 
active premenopausal women with menstrual disturbances, impaired endothelial function in 
the lower limb vasculature is associated with decrements in lumbar BMD, and vice versa.  
These alterations were commonly linked with low estrogen exposure, but not markers of 
oxidative stress or energy status. These findings suggest that in physically active women 
with menstrual disturbances: 1) estrogen deficiency may be a shared mechanism of 
pathophysiology in cardiovascular and bone health; 2) impairments in peripheral endothelial 
function may predict early unfavorable changes in bone metabolism, or vice versa; and 3) 
the known favorable bone and vascular adaptations to exercise training appear to be 
obviated.  Whether early changes in bone or vascular health can predict future risk of 
cardiovascular disease or osteoporosis, respectively, remains to be determined.  
Notwithstanding, current health guidelines recommend regular exercise for the prevention of 
osteoporosis and cardiovascular disease 40.  Thus, studies designed to investigate the 
independent and shared mechanisms of altered bone metabolism and vascular function in 
young women with exercise-associated menstrual disturbances is of clinical importance.  
Such studies may help further our understanding of the early origins of, and possible 
connections between, cardiovascular disease and osteoporosis in women that are 
independent of the effects of ageing and other shared risk factors for these diseases. 
 
Perspective 
Menstrual disturbances are commonly reported in recreational and competitive athletes 12.  
Both the Female Athlete Triad and the Relative Energy Deficiency Syndrome identify that 
functionally altered menstrual status in physically active women is primarily attributed to 
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chronic energy deficiency in association with high energy expenditure combined with 
insufficient caloric intake 15,41.  The known clinical consequences of altered menstrual status 
include decreased BMD 15,41.  Impaired endothelial function, a permissive factor in the 
development of atherosclerosis, has also been reported in amenorrheic athletes 10,23.  For 
the first time, we report a bidirectional association between lumbar BMD and peripheral 
endothelial function in recreationally active women with amenorrhea and anovulatory 
menstrual cycles. These associations were shown to be commonly linked with decreased 
estrogen exposure.  Although it is not yet known whether subclinical changes in bone health 
can be used as a surrogate for impaired vascular health and/or increased future risk of 
cardiovascular disease, these findings may be of relevance in the early detection and 
prevention of cardiovascular and bone health decrements in otherwise healthy young 
women.  Given that anovulatory menstrual cycles are asymptomatic, and are common 
among physically active women, these associations may be of particular importance to this 
group of women.  
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Table 1. Subject characteristics. 
  E2Rep E2Def P (main 
  (n=14) (n=13) effect) 
Demographics    
Age (years) 24.7 ± 0.9 23.9 ± 1.3 0.622 
Age of menarche (years) 12.2 ± 0.3 13.2 ± 0.4 0.037 
Weight (kg) 57.5 ± 1.3 57.7 ± 1.5 0.902 
Height (cm) 164.8 ± 1.3 166.6 ± 1.3 0.445 
BMI (kg/m2) 21.3 ± 0.4 20.9 ± 0.5 0.618 
Body fat (%) 24.3 ± 1.3 21.7 ± 1.9 0.281 
FFM (kg) 40.9 ± 1.0  43.2 ± 0.9 0.112 
MAP (mmHg) 70.1 ± 1.5 65.9 ± 0.9 0.022 
HR (b/min) 56.1 ± 2.2 49.5 ± 2. 0.041 
VO2 peak (ml/kg/min) 46.3 ± 1.3 44.7 ± 1.3 0.429 
    
Urinary Reproductive Hormones    
E1G AUC (ng/ml) 2047.9 ± 256.4 834.3 ± 149.2 0.001 
E1G mean (ng/ml) 70.8 ± 10.1 33.5 ± 3.9 0.005 
PdG AUC (µg/ml) 65.3 ± 14.7 17.8 ± 3.2 0.004 
PdG mean AUC (µg/ml) 2.7 ± 0.7 0.6 ± 0.2 0.008 
    
Serum Biomarkers     
TT3 (nmol/L) 1.59 ± 0.05 1.36 ± 0.09 0.022 
Prolactin (mIU/L) 380.8 ± 78.7 270.2 ± 72.3 0.334 
OxLDL (U/I) 47.2 ± 2.3 42.5 ± 3.2 0.243 
CRP (mg/dL) 11.3 ± 3.0 7.4 ± 2.2 0.306 
Values are mean ± SEM.  
AUC, area under the curve; BMI, body mass index; CRP, c-reactive protein; EIG, urinary oestrone 3-
glucuronide; FFM, fat free mass; HR, resting heart rate; MAP, resting mean arterial pressure; OxLDL, 
oxidized low-density lipoprotein; PdG, pregnanediol 3-glucuronide; TT3, total triiodothyronine; VO2 
peak, peak oxygen uptake. 
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Table 2. Bone and calf blood flow measures for the groups. 
  E2Rep E2Def P (main  
  (n=14) (n=13) effect) 
Bone Mineral Density 
   L1-L4 BMD (g/cm2) 1.28 ± 0.05 1.11 ± 0.03 0.006 
L1-L4 BMD Z-score 1.05 ± 0.39 -0.46 ± 0.24 0.003 
Total body BMD (g/cm2) 1.20 ± 0.02 1.14 ± 0.02 0.036 
Total body BMD Z-score 1.24 ± 0.22 0.48 ± 0.21 0.020 
    
Serum Bone Markers    
Osteocalcin (ng/mL) 7.9 ± 0.9 10.3 ± 1.1 0.104 
U-CTX (µg/L) 176.9 ± 18.2 256.7 ± 24.1 0.013 
P1NP (µg/L) 109.8 ± 9.5 123.9 ± 15.4 0.426 
    
Calf Blood Flow 
   Resting CBF (ml/100ml/min) 4.52 ± 0.38 3.05 ± 0.34 0.008 
Peak CBF (ml/100ml/min) 48.97 ± 1.94 46.21 ± 3.67 0.513 
Values are mean±SEM. 
 
CTX, c-telopeptide; P1NP, procollagen type 1 N propeptide. 
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Table 3. Regression analysis (stepwise regression) of predictors of calf blood flow, and total body 
and lumbar bone mineral density. 
    B SE B β F ratio R2 R2 adj P 
L1-L4 BMD 
       
 
Intercept 0.876 0.171 
     
 
CBFrest 0.087 0.018 0.707 22.937 0.499 0.478 <0.001 
         
Total Body BMD 
       
 
Intercept 1.066 0.039 
     
 
CBFrest 0.029 0.01 0.523 8.656 0.273 0.242 0.007 
         CBF Resting 
       
 
Intercept -2.957 1.500 
     
 
L1-L4 BMD 5.022 1.199 0.624 20.444 0.482 0.458 <0.001 
 
Osteocalcin 0.127 0.045 0.371 17.083 0.519 0.583 <0.001 
  E1G AUC  0.004 0.000 0.245 14.827 0.679 0.633 <0.001 
 
CBF, calf blood flow; CBFrest, resting calf blood flow; E1G AUC, urinary oestrone 3-glucuronide area 
under the curve. 
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Figure 1. Scatterplots showing the relationship between calf blood flow and L1-L4 BMD (A), 
estrogen and L1-L4 BMD (B), and estrogen and calf blood flow (C) in estrogen deplete 
(closed circles) and estrogen replete (open circles) physically active premenopausal women. 
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